Table 1. Recommendations on priority and non-priority procedures for cervical cancer management during COVID-19 pandemic.

Priority	Non-priority
Surgery for early-stage cervical cancer—consider deferring until 4–8 weeks in regions with high COVID-19 risk. Radiation therapy is an acceptable altern‑ative in case of easy access to a radiation therapy facility.	Oncotic colpocytology for cervical cancer screening—can be postponed to preserve health care resources and minimise contact of an individual with health care units
Chemoradiation for locally advanced cervical cancer—delays for treatment initiation and conclusion have a negative impact on overall survival.	Systemic therapy after progression on first-line for metastatic cervical cancer—no overall survival benefit
First-line chemotherapy (with or without bevacizumab, according to availability) for patients with metastatic cervical cancer.	Neoadjuvant chemotherapy before chemoradiation for localised cervical cancer—should be avoided due to the lack of a clear benefit and the possibility of a detrimental effect.
Surgical or non-surgical procedures to treat urgent complications (e.g., bleeding) in patients with a potentially curative disease.	Follow-up visits after curative treatment—in case of asymptomatic patients, clinic visits can be postponed or replaced for telemedicine